Longitudinal monitoring of BCR-ABL transcript levels in peripheral blood of CML patients treated with tyrosine kinase inhibitors (TKI) revealed a typical biphasic response. This evidence concerns the gene BCR and chronic myelogenous leukemia, BCR-ABL1 positive.